阿里巴巴(09988.HK)徐宏:關停併轉部份業務 以降本增效
內媒報道,阿里巴巴(09988.HK)首席財務官徐宏在2022財年四季度及全年業績分析師電話會議上表示,過去財年,阿里巴巴花在技術相關成本費用超過1,200億元人民幣,以持續增強阿里雲在中國雲市場的領先地位,推進對下一代技術的探索。下一步,阿里巴巴會對部份業務進行「關停併轉」(即關閉、停辦、合併、轉產)以達致降本增效。
對於內地政府對平台經濟監管問題,阿里巴巴董事會主席兼首席執行官張勇表示,中央領導層已向市場傳遞非常明確的訊號,鼓勵平台經濟在經濟發展中發揮重要作用。集團亦將致力於自己的責任,承諾尤其在核心領域,讓消費者過上更好的生活,幫助商家,推動技術創新。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.